Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3442-3451

  McLornan, Donal P ^a   Barrett, Helen L ^a   Cummins, Robert ^a   McDermott, Ultan ^a   McDowell, Cliona ^a   Conlon, Susie J ^a   Coyle, Victoria M ^a   Van Schaeybroeck, Sandra ^a   Wilson, Richard ^a   Kay, Elaine W ^a   Longley, Daniel B ^a   Johnston, Patrick G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASPASE 8; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; FLUOROURACIL; FOLINIC ACID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77954236742     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0052     Document Type: Article

References (43)

1. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
2. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ, for the QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007;370:2020-9.
3. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
4. O'Connell JB, Maggard MAKo CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009;9:307-19.
7. Burton ER, Libutti SK. Targeting TNF-α for cancer therapy. J Biol 2009;8:85.
8. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
9. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85.
10. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30. (Pubitemid 37328939)
11. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247-54.
12. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
13. Hu WH, Johnson H, Shu HB. Activation of NF-κB by FADD, Casper, and caspase-8. J Biol Chem 2000;275:10838-44.
14. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000;10:640-8.
15. Galligan L, Longley DB, McEwan M, et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 2005;4:2026-36.
16. Wilson TR, McLaughlin KM, McEwan M, et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 2007;67:5754-62.
17. Longley DB, Wilson TR, McEwan M, et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006;25:838-48.
18. Ullenhag GJ, Mukherjee A, Watson NF, et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007;13:5070-5.
19. Korkolopoulou P, Saetta AA, Levidou G, et al. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 2007;51:150-6.
20. van Geelen CM, Westra JL, de Vries EG, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004.
21. Strater J, Hinz U, Walczak H, et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002;8:3734-40.
22. Heijink DM, Kleibeuker JH, Jalving M, et al. Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas. Cell Oncol 2007;29:409-19. (Pubitemid 47255979)
23. Xu B, Zhou ZG, Li Y, et al. Clinicopathological significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology 2008;74:229-36.
24. McDermott U, Boyd RE, Houston RF, et al. A phase III trial of short duration adjuvant chemotherapy with bolus/infusional 5-fluorouracil and folinic acid versus surgery alone in Dukes' B and C colorectal cancer. Proc Am Soc Clin Oncol 2003;22, Abstract #339.
25. Koornstra JJ, Kleibeuker JH, van Geelen CM, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-35.
26. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430-8.
27. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
28. Vasilevskaya IA, O'Dwyer PJ. 17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharmacol 2005;70:580-9.
29. Lippa MS, Strockbine LD, Le TT, et al. Expression of anti-apoptotic factors modulates Apo2L/TRAIL resistance in colon carcinoma cells. Apoptosis 2007;12:1465-78.
30. Yoo J, Lee YJ. Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells. J Cell Biochem 2008;103:98-109.
31. Zhu H, Zhang L, Huang X, et al. Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms. Mol Ther 2004;9:666-73.
32. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Fas counter-attack - the best form of tumor defense? Nat Med 1999;5:267-8.
33. Ryan AE, Shanahan F, O'Connell J, Houston AM. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. Cancer Res 2005;65:9817-23.
34. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-20.
35. Giovarelli M, Musiani P, Garotta G, et al. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol 1999;163:4886-93.
36. Ishimura N, Isomoto H, Bronk SF, Gores GJ. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 2006;290:G129-36.
37. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 2003;22:3842-52.
38. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008;27:6207-15.
39. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol Cell Biol 2004;24:2627-36.
40. Frisch SM. Caspase-8: fly or die. Cancer Res 2008;68:4491-3.
41. Bell BD, Leverrier S, Weist BM, et al. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci U S A 2008;105:16677-82.
42. Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death Differ 2003;10:356-64.
43. Ryu BK, Lee MG, Chi SG, Kim YW, Park JH. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol 2001;194:15-9.